Amy Dréan - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Amy Dréan

Showing results (1-10 of 3) with videos related to

Pageof 1

Sort By:

Critical Reviews in Oncology/Hematology|December 10, 2016

PARP inhibitor combination therapyAmy Dréan, Christopher J Lord, Alan Ashworth

Molecular Cancer Therapeutics|June 17, 2017

Modeling Therapy Resistance in <i>BRCA1/2</i>-Mutant CancersAmy Dréan, Chris T Williamson, Rachel Brough, et al.

Nature Communications|May 12, 2018

Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistanceStephen J Pettitt, Dragomir B Krastev, Inger Brandsma, et al.

Pageof 1

Search research articles

Showing results (1-10 of 3) with videos related to

Sort By:

Pageof 1

Critical Reviews in Oncology/Hematology|December 10, 2016

PARP inhibitor combination therapyAmy Dréan, Christopher J Lord, Alan Ashworth

Molecular Cancer Therapeutics|June 17, 2017

Modeling Therapy Resistance in <i>BRCA1/2</i>-Mutant CancersAmy Dréan, Chris T Williamson, Rachel Brough, et al.

Nature Communications|May 12, 2018

Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistanceStephen J Pettitt, Dragomir B Krastev, Inger Brandsma, et al.

Pageof 1